NovaBay Pharmaceuticals, Inc. (NBY) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
NovaBay Pharmaceuticals, Inc. (NBY) Bundle
Looking to determine the intrinsic value of NovaBay Pharmaceuticals, Inc.? Our (NBY) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.6 | 9.9 | 8.4 | 14.4 | 14.7 | 18.7 | 23.8 | 30.3 | 38.5 | 48.9 |
| Revenue Growth, % | 0 | 50.54 | -15.23 | 71.05 | 2.24 | 27.15 | 27.15 | 27.15 | 27.15 | 27.15 |
| EBITDA | -9.3 | -6.4 | -8.7 | -7.2 | -4.8 | -13.0 | -16.5 | -21.0 | -26.7 | -33.9 |
| EBITDA, % | -141.46 | -64.17 | -103.82 | -49.97 | -32.6 | -69.35 | -69.35 | -69.35 | -69.35 | -69.35 |
| Depreciation | .1 | .1 | .1 | .5 | .2 | .3 | .4 | .5 | .6 | .7 |
| Depreciation, % | 0.985 | 0.51339 | 1.41 | 3.35 | 1.38 | 1.53 | 1.53 | 1.53 | 1.53 | 1.53 |
| EBIT | -9.4 | -6.4 | -8.9 | -7.7 | -5.0 | -13.2 | -16.8 | -21.3 | -27.1 | -34.4 |
| EBIT, % | -142.45 | -64.69 | -105.24 | -53.32 | -33.97 | -70.4 | -70.4 | -70.4 | -70.4 | -70.4 |
| Total Cash | 6.9 | 12.0 | 7.5 | 5.4 | 3.1 | 13.0 | 16.6 | 21.0 | 26.8 | 34.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.1 | 1.1 | 1.7 | 2.0 | .8 | 2.5 | 3.1 | 4.0 | 5.1 | 6.5 |
| Account Receivables, % | 16.15 | 11.13 | 19.81 | 13.7 | 5.15 | 13.19 | 13.19 | 13.19 | 13.19 | 13.19 |
| Inventories | .5 | .6 | 3.2 | 3.4 | 2.9 | 3.6 | 4.5 | 5.8 | 7.3 | 9.3 |
| Inventories, % | 7.46 | 6.12 | 38.24 | 23.86 | 19.54 | 19.04 | 19.04 | 19.04 | 19.04 | 19.04 |
| Accounts Payable | .3 | .3 | 1.0 | 1.1 | 1.1 | 1.3 | 1.7 | 2.2 | 2.7 | 3.5 |
| Accounts Payable, % | 5.02 | 3.04 | 12.41 | 7.5 | 7.67 | 7.13 | 7.13 | 7.13 | 7.13 | 7.13 |
| Capital Expenditure | .0 | .0 | -.1 | -.1 | .0 | -.1 | -.1 | -.1 | -.2 | -.2 |
| Capital Expenditure, % | -0.28792 | -0.26173 | -0.6175 | -0.77756 | -0.12902 | -0.41475 | -0.41475 | -0.41475 | -0.41475 | -0.41475 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -10.2 | -6.4 | -10.0 | -11.8 | -5.0 | -13.2 | -16.8 | -21.3 | -27.1 | -34.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -11.4 | -6.6 | -12.3 | -11.9 | -3.0 | -15.2 | -17.8 | -22.6 | -28.7 | -36.5 |
| WACC, % | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 | 4.54 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -103.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -37 | |||||||||
| Terminal Value | -1,469 | |||||||||
| Present Terminal Value | -1,177 | |||||||||
| Enterprise Value | -1,281 | |||||||||
| Net Debt | 0 | |||||||||
| Equity Value | -1,281 | |||||||||
| Diluted Shares Outstanding, MM | 0 | |||||||||
| Equity Value Per Share | -10,634.33 |
What You Will Get
- Pre-Filled Financial Model: NovaBay Pharmaceuticals' actual data enables precise DCF valuation.
- Full Forecast Control: Adjust revenue growth, margins, WACC, and other key drivers specific to (NBY).
- Instant Calculations: Automatic updates ensure you see results as you make changes for (NBY).
- Investor-Ready Template: A refined Excel file designed for professional-grade valuation of (NBY).
- Customizable and Reusable: Tailored for flexibility, allowing repeated use for detailed forecasts related to (NBY).
Key Features
- 🔍 Real-Life NBY Financials: Pre-filled historical and projected data for NovaBay Pharmaceuticals, Inc. (NBY).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate NovaBay’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize NovaBay’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download: Obtain the pre-formulated Excel file containing NovaBay Pharmaceuticals' (NBY) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and instantly compare the results.
- Make Decisions: Leverage the valuation findings to inform your investment approach.
Why Choose NovaBay Pharmaceuticals, Inc. (NBY)?
- Innovative Solutions: Cutting-edge products designed to meet modern healthcare challenges.
- Proven Efficacy: Clinical studies demonstrate the effectiveness of our pharmaceutical offerings.
- Commitment to Quality: Rigorous quality control processes ensure the highest standards in our products.
- Patient-Centric Approach: We prioritize patient needs and outcomes in our research and development.
- Backed by Expertise: Our team comprises industry veterans dedicated to advancing healthcare.
Who Should Use NovaBay Pharmaceuticals, Inc. (NBY)?
- Healthcare Investors: Make informed decisions with a reliable analysis of pharmaceutical valuations.
- Market Analysts: Streamline your research with comprehensive data and insights tailored for the biotech sector.
- Consultants: Effortlessly modify reports and presentations to showcase NovaBay's market position and potential.
- Biotech Enthusiasts: Enhance your knowledge of the pharmaceutical industry through detailed case studies and examples.
- Educators and Students: Utilize it as a valuable resource for learning about pharmaceutical economics and valuation methodologies.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled NovaBay Pharmaceuticals (NBY) historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for NovaBay Pharmaceuticals (NBY).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.